A 4-week double-blind placebo-controlled pilot study, evaluating niacin-induced flushing and lipid parameter effects of V0002 CA 1g 3 capsules/day associated with Niaspan® (from 375 mg to 1000 mg) in addition to usual care statin, in patients suffer
A 4-week double-blind placebo-controlled pilot study, evaluating niacin-induced flushing and lipid parameter effects of V0002 CA 1g 3 capsules/day associated with Niaspan® (from 375 mg to 1000 mg) in addition to usual care statin, in patients suffer
A 4-week double-blind placebo-controlled pilot study, evaluating niacin-induced flushing and lipid parameter effects of V0002 CA 1g 3 capsules/day associated with Niaspan® (from 375 mg to 1000 mg) in addition to usual care statin, in patients suffering from dyslipidemia with uncontrolled elevated triglycerides
Statut
Status :
Terminé
Type d'étude
Phase II
Age Min.
18
Ans
Age Max.
30
Ans
Genre
Homme
Aire thérapeutique :
Anomalies sanguines
Maladie :
Dyslipidémie
Traitement :
V0312
Phase :
Phase II
Date de début de l'étude :
28 Avril 2008
End date :
02 Septembre 2008
Identifiant de l'essai :
V00312 CA 201
Identifiant EudraCT/CTIS :
2007-006393-29
Envoyer par email